Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | YAP1 | P46937 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824802 | 0.85 | KLK5 (0.52) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL14885696 | 0.85 | KLK5 (0.52) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL1824223 | 0.85 | KLK5 (0.52) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL29103443 | 0.84 | KLK5 (0.61) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL2294118 | 0.84 | KLK5 (0.61) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL2294112 | 0.84 | KLK5 (0.61) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL29721250 | 0.84 | KLK5 (0.61) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL2293357 | 0.83 | KLK5 (0.52) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL4087401 | 0.83 | KLK5 (0.54) | BCL2KLK5ITGB3ITGA2BCTSS | |
| SCHEMBL2292276 | 0.83 | KLK5 (0.52) | BCL2KLK5ITGB3ITGA2BCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319031-A1 | Novel Tyrosine Derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED | 2008-12-25 | — | — | US | disclosed |
| EP-1858845-A2 | NOVEL TYROSINE DERIVATIVES | Orchid Chemicals and Pharmaceuticals Limited (IN) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006097809-A2 | NOVEL TYROSINE DERIVATIVES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319031-A1 | Novel Tyrosine Derivatives | ABL1, LCK, TYRO3 | BCL2 2159/4885KLK5 2087/4885ITGB3 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.